BioNanomatrix to Introduce nanoAnalyzerÂ® 1000 System
PHILADELPHIA, Oct. 27 /PRNewswire/ — BioNanomatrix, Inc., which is developing and commercializing breakthrough single-molecule genomic analysis technology, will introduce next month the nanoAnalyzer 1000 System at the American Society of Human Genetics (ASHG) Annual Meeting from November 2-6, 2010 in Washington, D.C.
The nanoAnalyzer 1000 System is intended for advanced analyses of DNA and other macromolecules and consists of a disposable nanochannel silicon-based device, analytical instrumentation, software and reagents. The system is currently being tested in collaboration with leading researchers in the genomics field.
“This event is the culmination of several years of effort to develop a complete system for state-of-the-art analyses of DNA and potentially other large molecules of biological interest,” said Edward L. Erickson, BioNanomatrix’s president and chief executive officer. “We expect to make the nanoAnalyzer 1000 System available to early access customers following the New Year.”
The company further announced that it is developing a wide range of applications for the nanoAnalyzer 1000 System, including:
- Assessment of DNA sample quality for advanced sequencing and other genomic analysis methods;
- Assessment of DNA damage induced by environmental factors such as ionizing radiation and pollutants;
- Adjunctive methods for assisting researchers in genome assembly, assembly validation, finishing and scaffolding; and
- Identification and analysis of structural variations in genomic DNA.
The nanoAnalyzer 1000 System on display at Booth #723 at ASHG, which is being held at the Walter E. Washington Convention Center in Washington, D.C. Inquiries concerning the company and its products should be addressed to firstname.lastname@example.org.
BioNanomatrix, Inc., a privately held genomics company, is developing and commercializing game-changing, proprietary technologies for analysis of large biological molecules, such as nucleic acids that are extremely important in life science research, clinical diagnostic applications, and development of new therapeutics. This technology is designed to reduce dramatically the time and complexity to analyze the genome and provide additional information, including structural variation data. BioNanomatrix’s products will provide users with the means to perform many single-molecule analyses on minute biological samples that are essentially impossible, impractical or too expensive with current technology. For more information, visit: www.bionanomatrix.com.
Note: NANOANALYZER is a registered trademark of BioNanomatrix, Inc. The names of other companies, other entities, products and/or services mentioned herein may be the trademarks of their respective owners.
Media Contact: Tiberend Strategic Advisors, Inc. (212) 827-0020 Farrell Denby email@example.com or Andrew Mielach firstname.lastname@example.org
SOURCE BioNanomatrix, Inc.